Kate A. Markey

Kate A. Markey

Auto-generated profile, based on publicly available information

Kate A. Markey

Fred Hutchinson Cancer Center, Seattle, Washington, United States

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2019 in Science
Verified
Journal Article
Closed access
PDF file
CSC. K. Stein-Thoeringer
C. K. Stein-Thoeringer
KNK. B. Nichols
K. B. Nichols
ALA. Lazrak
A. Lazrak
MDM. D. Docampo
M. D. Docampo
ASA. E. Slingerland
A. E. Slingerland
MBM. R. M. van Den Brink
M. R. M. van Den Brink
Lactose can fuel GVHD: Allogeneic hematopoietic cell transplantation (allo-HCT) is used to treat certain hematopoietic malignancies, but patients have a risk of developing graft-versus-host disease (GVHD). Stein-Thoeringer et al. performed a large-scale analysis of more than 1300 patients treated with allo-HCT across four clinical centers (see the Perspective by Zitvogel and Kroemer). High levels of bacteria from the Enterococcus genus were associated with greater incidence of GVHD and mortality. Lactose appears to provide a substrate for Enterococcus growth, and patients with a lactose-malabsorption genotype had a greater abundance of Enterococcus. A lactose-free diet limited Enterococcus growth, reduced the severity of GVHD, and improved survival in gnotobiotic mouse models. Science , this issue p. 1143 ; see also p. 1077

29 November 2011 in Nature Medicine
Verified
Journal Article
Closed access
MKMotoko Koyama
Motoko Koyama
RKRachel D Kuns
Rachel D Kuns
SOStuart D Olver
Stuart D Olver
NRNeil C Raffelt
Neil C Raffelt
YWYana A Wilson
Yana A Wilson
GHGeoffrey R Hill
Geoffrey R Hill

2 July 2020 in Blood
Verified
Journal Article
Open access
PDF file
KMKate A. Markey
Kate A. Markey
JSJonas Schluter
Jonas Schluter
AGAntonio Gomes
Antonio Gomes
ELEric R. Littmann
Eric R. Littmann
APAmanda J. Pickard
Amanda J. Pickard
MBMarcel R. M. van Den Brink
Marcel R. M. van Den Brink
Studies of the relationship between the gastrointestinal microbiota and outcomes in allogeneic hematopoietic stem cell transplantation (allo-HCT) have thus far largely focused on early complications, predominantly infection and acute graft-versus-host disease (GVHD). We examined the potential relationship of the microbiome with chronic GVHD (cGVHD) by analyzing stool and plasma samples collected late after allo-HCT using a case-control study design. We found lower circulating concentrations of the microbe-derived short-chain fatty acids (SCFAs) propionate and butyrate in day 100 plasma samples from patients who developed cGVHD, compared with those who remained free of this complication, in the initial case-control cohort of transplant patients and in a further cross-sectional cohort from an independent transplant center. An additional cross-sectional patient cohort from a third transplant center was analyzed; however, serum (rather than plasma) was available, and the differences in SCFAs observed in the plasma samples were not recapitulated. In sum, our findings from the primary case-control cohort and 1 of 2 cross-sectional cohorts explored suggest that the gastrointestinal microbiome may exert immunomodulatory effects in allo-HCT patients at least in part due to control of systemic concentrations of microbe-derived SCFAs.

5 August 2010 in Blood
Verified
Journal Article
Closed access
PDF file
GHGeoffrey R. Hill
Geoffrey R. Hill
SOStuart D. Olver
Stuart D. Olver
RKRachel D. Kuns
Rachel D. Kuns
AVAntiopi Varelias
Antiopi Varelias
NRNeil C. Raffelt
Neil C. Raffelt
KMKelli P. A. MacDonald
Kelli P. A. MacDonald
The recent shift to the use of stem cells mobilized by granulocyte colony-stimulating factor (G-CSF) for hematopoietic transplantation has increased chronic graftversus-host disease (GVHD), although the mechanisms of this are unclear. We have found that G-CSF invokes potent type 17 rather than type 1 or type 2 differentiation. The amplification of interleukin-17 (IL-17) production by G-CSF occurs in both CD4 and CD8 conventional T cells and is dependent on, and downstream of, G-CSF–induced IL-21 signaling. Importantly, donor IL-17A controls the infiltration of macrophages into skin and cutaneous fibrosis, manifesting late after transplantation as scleroderma. Interestingly, donor CD8 T cells were the predominant source of IL-17A after transplantation and could mediate scleroderma independently of CD4 T cells. This study provides a logical explanation for the propensity of allogeneic stem cell transplantation to invoke sclerodermatous GVHD and suggests a therapeutic strategy for intervention.

15 November 2013 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
Ping ZhangPing Zhang
Ping Zhang
STSiok-Keen Tey
Siok-Keen Tey
MKMotoko Koyama
Motoko Koyama
RKRachel D. Kuns
Rachel D. Kuns
SOStuart D. Olver
Stuart D. Olver
GHGeoffrey R. Hill
Geoffrey R. Hill
Natural regulatory T cells (nTregs) play an important role in tolerance; however, the small numbers of cells obtainable potentially limit the feasibility of clinical adoptive transfer. Therefore, we studied the feasibility and efficacy of using murine-induced regulatory T cells (iTregs) for the induction of tolerance after bone marrow transplantation. iTregs could be induced in large numbers from conventional donor CD4 and CD8 T cells within 1 wk and were highly suppressive. During graft-versus-host disease (GVHD), CD4 and CD8 iTregs suppressed the proliferation of effector T cells and the production of proinflammatory cytokines. However, unlike nTregs, both iTreg populations lost Foxp3 expression within 3 wk in vivo, reverted to effector T cells, and exacerbated GVHD. The loss of Foxp3 in iTregs followed homeostatic and/or alloantigen-driven proliferation and was unrelated to GVHD. However, the concurrent administration of rapamycin, with or without IL-2/anti–IL-2 Ab complexes, to the transplant recipients significantly improved Foxp3 stability in CD4 iTregs (and, to a lesser extent, CD8 iTregs), such that they remained detectable 12 wk after transfer. Strikingly, CD4, but not CD8, iTregs could then suppress Teff proliferation and proinflammatory cytokine production and prevent GVHD in an equivalent fashion to nTregs. However, at high numbers and when used as GVHD prophylaxis, Tregs potently suppress graft-versus-leukemia effects and so may be most appropriate as a therapeutic modality to treat GVHD. These data demonstrate that CD4 iTregs can be produced rapidly in large, clinically relevant numbers and, when transferred in the presence of systemic rapamycin and IL-2, induce tolerance in transplant recipients.

28 February 2013 in Blood
Verified
Journal Article
Closed access
PDF file
CSCyril Seillet
Cyril Seillet
JJJacob T. Jackson
Jacob T. Jackson
KMKate A. Markey
Kate A. Markey
HBHugh J. M. Brady
Hugh J. M. Brady
GHGeoffrey R. Hill
Geoffrey R. Hill
GBGabrielle T. Belz
Gabrielle T. Belz
Antiviral immunity and cross-presentation is mediated constitutively through CD8α+ and CD103+ DCs. Development of these DC subsets is thought to require the transcription factors Irf8, Id2, Nfil3, and Batf3, although how this network is regulated is poorly defined. We addressed the nature of the differentiation blocks observed in the absence of these factors and found that although all 4 factors are required for CD103+ DC development, only Irf8 is essential for CD8α+ DCs. CD8α+ DCs emerged in the absence of Id2, Nfil3 and Batf3 in short-term bone marrow reconstitution. These “induced” CD8α+ DCs exhibit several hallmarks of classic CD8α+ DCs including the expression of CD24, Tlr3, Xcr1, Clec9A, and the capacity to cross-present soluble, cell-associated antigens and viral antigens even in the absence of Batf3. Collectively, these results uncover a previously undescribed pathway by which CD8α+ DCs emerge independent of Id2, Nfil3, and Batf3, but dependent on Irf8. Key Points Transcription factors Batf3, Id2, and Nfil3 are not essential for induced CD8α+ DC generation. Induced CD8α+ DCs can cross-present cellular antigens.